Nuo Therapeutics, Inc. (AURX) Form 8-K — May 14, 2026
Nuo Therapeutics reported first-quarter 2026 revenues of approximately $1.3 million, representing a 169% increase year-over-year and a 20% increase sequentially from the fourth quarter of 2025. This growth was primarily driven by product sales of $1.22 million, with Aurix branded product revenues rising over 30% sequentially. The company reported a net loss of $618,466 for the quarter, a significant improvement from the $746,128 net loss in the same period of 2025. Operating losses narrowed to $446,466 from $745,147, reflecting improved gross margins and operational efficiency amidst a changing reimbursement landscape for skin substitutes.
Key figures
- Revenue
- 1302115
- Revenue Yoy
- 169%
- Cash Position
- 263827
- Loan amount
- 1000000
- Gross profit
- 849727
- Product revenue
- 1224174
- Shares outstanding
- 48289296
- Distribution fee revenue
- 77941
Price after filing
Close on the filing date to close N calendar days later (from $1.35). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.